Candriam S.C.A. Sells 4,400 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Candriam S.C.A. lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,607 shares of the medical equipment provider’s stock after selling 4,400 shares during the quarter. Candriam S.C.A. owned about 0.16% of Lantheus worth $10,163,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its position in shares of Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after purchasing an additional 257,022 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Reinhart Partners LLC. boosted its position in shares of Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Swedbank AB boosted its position in shares of Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC boosted its position in shares of Lantheus by 6.1% during the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock worth $73,629,000 after purchasing an additional 38,776 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $106.34 on Friday. The firm has a market cap of $7.28 billion, a price-to-earnings ratio of 17.69 and a beta of 0.44. Lantheus Holdings, Inc. has a 52 week low of $56.44 and a 52 week high of $126.89. The firm has a 50-day moving average price of $90.43 and a two-hundred day moving average price of $96.80.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LNTH. Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.